ArticleRSC advances2025
Reusing the expired Ceftazidime drug as an inhibiting agent for zinc metal corrosion in HCl medium.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug disposal costs and drug-related environmental pollution could be reduced by reusing expired drugs. A well-known cephalosporin antibiotic that was listed as an essential medication by the World Health Organization is Ceftazidime. In this study, the corrosion mitigation properties of the expired Ceftazidime (CDZ) drug for zinc corrosion in 1 mol per L HCl solution were examined by weight loss (WL), frequency modulation (EFM), potentiodynamic polarization (PDP), and impedance spectroscopy (EIS) techniques. Theoretical calculations were carried out by Density Functional Tight Binding (DFTB) and Monte Carlo (MC) simulations. Furthermore, scanning electron microscopy (SEM) and energy dispersion X-rays (EDX) were used for examining the appearance and structure of the corroded zinc surface, respectively. For a CDZ concentration of 300 ppm, EFM techniques have shown an inhibitive efficiency (IE) of 70.3% at 298 K. The IE increased as the drug concentration increased from 50 to 300 ppm, whereas it reduced as the temperature increased. The inhibition effect ceased to improve at concentrations greater than 300 ppm. A mixed form of adsorption (physisorption and chemisorption) was suggested for inhibition. The adsorption process followed the Temkin model. The spontaneous character and exothermicity of the adsorption process were demonstrated by the and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.